KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.

Suzanne George, Jean-Yves Blay, Ping Chi, Robin L Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John R Zalcberg, William Reichmann, Kam Sprott, Paulina Cox, Matthew L Sherman, Rodrigo Ruiz-Soto, Michael C Heinrich, Sebastian Bauer

Future Oncol 20(27) 1973-1982

PMID39229786
PMCIDPMC11497949
DOI10.1080/14796694.2024.2376521
发表日期2024-09-04
摘要

摘要

Somatic KIT activating mutations drive most gastrointestinal stromal tumors (GISTs). Disease progression eventually develops with first-line imatinib, commonly due to KIT secondary mutations, and different kinase inhibitors have various levels of treatment efficacy dependent on specific acquired resistance mutations. Ripretinib is a broad-spectrum switch-control KIT/PDGFRA tyrosine kinase inhibitor for patients with advanced GIST who received prior treatment with three or more kinase inhibitors, including imatinib. Exploratory baseline circulating tumor DNA analysis from the second-line INTRIGUE trial determined that patients with advanced GIST previously treated with imatinib harboring primary KIT exon 11 mutations and secondary resistance mutations restricted to KIT exons 17/18 had greater clinical benefit with ripretinib versus sunitinib. We describe the rationale and design of INSIGHT (NCT05734105), an ongoing Phase III open-label study of ripretinib versus sunitinib in patients with advanced GIST previously treated with imatinib exclusively harboring KIT exon 11 + 17/18 mutations detected by circulating tumor DNA.Clinical Trial Registration: NCT05734105 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。